Stroke
Conditions
Interventions
Sham stimulus group:rTMS sham stimulation of the affected hemisphere based on conventional rehabilitation methods, 1 time/day, 20 min/time, 5 times/week, for 2 weeks
Low Frequency Group:1 Hz low-frequency rTMS stimulation of the affected hemisphere, 1 time/day, 20 min/time, 5 times/week, for 2 weeks, based on conventional rehabilitation training methods
High Frequency Group:High-frequency rTMS stimulation at 10 Hz in the healthy hemisphere, 1 time/day, 20 min/time, 5 times/week, for 2 weeks, based on conventional rehabilitation training methods
Combined low and high frequency group:Based on the conventional rehabilitation training method, the affected hemisphere was stimulated with 1 Hz low frequency for 10 min, and then the healthy hemisphe
Sponsors
General Hospital of Ningxia Medical University
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. The diagnosis of stroke conforms to the relevant standards of the Chinese Guidelines for the Diagnosis and Treatment of Cerebral Hemorrhage (2014) or the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke (2018), and is confirmed by brain CT or MRI as unilateral cerebral hemisphere or infratentorial stroke; 2. Patients with a course of disease <= 6 months, stable condition and clear consciousness, who can cooperate with physical examination, scoring and treatment; 3. Primary and unilateral onset; 4. Age: 20-80 years; 5. Brunstrom stage of upper limb: 2-5 stages; 6. The patient and his family are willing to accept transcranial magnetic stimulation treatment and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with unstable condition, progressive stroke, malignant progressive hypertension or secondary cerebral hemorrhage after cerebral infarction; 2. There is obvious indication of increased intracranial pressure; 3. There are contraindications for transcranial magnetic stimulation treatment, such as epilepsy, implantation of pacemaker or drug pump, metal objects in skull or eyes, etc; 4. Patients with cognitive impairment; 5. Patients with malignant tumor; 6. Patients with severe lung, heart, liver and kidney dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fugl-Meyer Assessment Upper Extremity Scale,FMA-UE;Latency of action evoked potentials;Brain derived neurotrophic factor (BDNF); | — |
Secondary
| Measure | Time frame |
|---|---|
| MBI;Modified Ashworth Spasm (MAS);National Institutes of Health Stroke Scale (NIHSS);Brunnstrom staging;Brain derived neurotrophic factor precursor protein (Pro-BDNF);Matrix metalloproteinase-9 (MMP-9);central motor conduction time; | — |
Countries
China
Contacts
Public ContactNing Zhu
General Hospital of Ningxia Medical UniversityKYLL
Outcome results
None listed